Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antipsychotic medication |
| gptkbp:approvedBy |
gptkb:Australia
gptkb:China gptkb:Europe gptkb:France gptkb:India 1990s |
| gptkbp:ATCCode |
N05AL05
|
| gptkbp:brand |
Solian
Amipride Amitrex Amodal Barhemsys Deniban Socian Soltus Sulpitac |
| gptkbp:CASNumber |
71675-85-9
|
| gptkbp:chemicalFormula |
C17H27N3O4S
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:Sanofi-Aventis
|
| gptkbp:drugClass |
antipsychotic medication
benzamide |
| gptkbp:eliminationHalfLife |
12 hours
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
amisulpride
|
| gptkbp:IUPACName |
4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
|
| gptkbp:KEGGID |
gptkb:D07451
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
dopamine D3 receptor antagonist |
| gptkbp:metabolism |
minimal hepatic metabolism
|
| gptkbp:molecularWeight |
369.48 g/mol
|
| gptkbp:PubChem_CID |
2159
CHEMBL1407 DB06210 |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
gptkb:hyperprolactinemia
nausea anxiety constipation weight gain insomnia extrapyramidal symptoms sexual dysfunction |
| gptkbp:UNII |
7T59J1MMK7
|
| gptkbp:usedFor |
schizophrenia
acute psychosis depression (off-label) |
| gptkbp:bfsParent |
gptkb:N05AX
|
| gptkbp:bfsLayer |
7
|